SRNE - Sorrento' COVISHIELD shows neutralizing activity vs Omicron subvariants

Sorrento Therapeutics (SRNE +0.5%) said additional preclinical results showed broad spectrum COVISHIELD (STI-9167) neutralizing activity against Omicron BA.1, Omicron BA.1+R346K, and the increasingly prevalent sublineage, Omicron BA.2. The company added that an investigational new drug application for COVISHIELD IN, formulated for intranasal (IN) administration for clinical use in early symptomatic and asymptomatic infections, was submitted to the FDA on Feb. 1. The company said COVISHIELD (STI-9167) is an intravenous formulation and COVISHIELD IN (STI-9199) is a proprietary IN formulation of COVISHIELD.

For further details see:

Sorrento' COVISHIELD shows neutralizing activity vs Omicron subvariants